Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSV-ALLO in Lupus Nephritis
2024-514750-67-00Phase 3Authorised
- Sponsor
- Hospital Universitario Rio Hortega
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing MSV-ALLO with Placebo (2 arms). Primary endpoint: Renal response at week 24. Planned start Nov 2024; status: authorised.
02
Drugs
MSV-allo
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-514750-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514750-67-00.